Lumvoa (veligrotug-vvze)
Viridian Therapeutics (VRDN)
ApprovedJun 26, 2026
Marketer take
A second thyroid eye disease biologic after Tepezza, so ophthalmologists, oculoplastic surgeons and endocrinologists will see head-to-head differentiation messaging.
- Sponsor company
- Viridian Therapeutics (VRDN)
- Indication
- To treat thyroid eye disease
- Therapeutic area
- Ophthalmology, Immunology
- Event
- FDA approval
- Date
- Jun 26, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?